Global Blood secures FDA approval for new pill to treat sickle cell disease
JANICE HANEY CARR/CDC/SICKLE CELL FOUNDATION OF GEORGIA VIA AP
The novel drug was developed by the biotech firm Global Blood Therapeutics and will be sold under the brand name Oxbryta.
No hay comentarios:
Publicar un comentario